Clinical characteristics of patients with early-stage NKTCL before and after PSM stratification by RT modality
| . | IMRT group . | 3D-CRT group . | P . |
|---|---|---|---|
| Before PSM | |||
| Total | 981 | 710 | |
| Male | 689 (70.2) | 498 (70.1) | .967 |
| Age >60 y | 120 (12.2) | 95 (13.4) | .484 |
| B symptoms | 378 (38.5) | 255 (35.9) | .273 |
| Elevated LDH | 228 (23.2) | 210 (29.6) | .003 |
| ECOG ≥2 | 31 (3.2) | 38 (5.4) | .025 |
| Stage II | 355 (36.2) | 170 (23.9) | <.001 |
| PTI | 554 (56.5) | 363 (51.1) | .029 |
| After PSM | |||
| Total | 649 | 649 | |
| Male | 453 (69.8) | 453 (69.8) | 1.000 |
| Age >60 y | 79 (12.2) | 79 (12.2) | 1.000 |
| B symptoms | 226 (34.8) | 226 (34.8) | 1.000 |
| Elevated LDH | 162 (25.0) | 162 (25.0) | 1.000 |
| ECOG ≥2 | 15 (2.3) | 15 (2.3) | 1.000 |
| Stage II | 162 (25.0) | 162 (25.0) | 1.000 |
| PTI | 330 (50.8) | 330 (50.8) | 1.000 |
| . | IMRT group . | 3D-CRT group . | P . |
|---|---|---|---|
| Before PSM | |||
| Total | 981 | 710 | |
| Male | 689 (70.2) | 498 (70.1) | .967 |
| Age >60 y | 120 (12.2) | 95 (13.4) | .484 |
| B symptoms | 378 (38.5) | 255 (35.9) | .273 |
| Elevated LDH | 228 (23.2) | 210 (29.6) | .003 |
| ECOG ≥2 | 31 (3.2) | 38 (5.4) | .025 |
| Stage II | 355 (36.2) | 170 (23.9) | <.001 |
| PTI | 554 (56.5) | 363 (51.1) | .029 |
| After PSM | |||
| Total | 649 | 649 | |
| Male | 453 (69.8) | 453 (69.8) | 1.000 |
| Age >60 y | 79 (12.2) | 79 (12.2) | 1.000 |
| B symptoms | 226 (34.8) | 226 (34.8) | 1.000 |
| Elevated LDH | 162 (25.0) | 162 (25.0) | 1.000 |
| ECOG ≥2 | 15 (2.3) | 15 (2.3) | 1.000 |
| Stage II | 162 (25.0) | 162 (25.0) | 1.000 |
| PTI | 330 (50.8) | 330 (50.8) | 1.000 |
Data are n (%).